These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 30455394

  • 1. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
    Zhang P, Chen XB, Ding BQ, Liu HL, He T.
    Biosci Rep; 2018 Dec 21; 38(6):. PubMed ID: 30455394
    [Abstract] [Full Text] [Related]

  • 2. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C, Feng S, Chen L.
    Mol Cell Biochem; 2021 Feb 21; 476(2):699-713. PubMed ID: 33106913
    [Abstract] [Full Text] [Related]

  • 3. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
    Guo L, Wu Z.
    Neuropathology; 2022 Oct 21; 42(5):430-446. PubMed ID: 35701983
    [Abstract] [Full Text] [Related]

  • 4. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.
    Ma Y, Zhou G, Li M, Hu D, Zhang L, Liu P, Lin K.
    Neurochem Int; 2018 Sep 21; 118():233-241. PubMed ID: 29572052
    [Abstract] [Full Text] [Related]

  • 5. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H, Cui X.
    Cancer Biother Radiopharm; 2021 Sep 21; 36(7):556-567. PubMed ID: 32833501
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 8. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
    Li H, Liu Q, Chen Z, Wu M, Zhang C, Su J, Li Y, Zhang C.
    Cell Death Dis; 2021 Mar 05; 12(3):252. PubMed ID: 33674567
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
    Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, Kuwayama K, Nagahiro S, Takagi Y.
    J Neurooncol; 2018 Sep 05; 139(2):323-332. PubMed ID: 29779087
    [Abstract] [Full Text] [Related]

  • 10. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X, Wang M, Zuo J, Wahafu A, Mao P, Li R, Wu W, Xie W, Wang J.
    Life Sci; 2019 Nov 01; 236():116917. PubMed ID: 31614149
    [Abstract] [Full Text] [Related]

  • 11. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M, Diesler K, Majhen D, Steigerwald C, Berte N, Freund H, Stojanović N, Kaina B, Osmak M, Ambriović-Ristov A, Tomicic MT.
    Oncotarget; 2017 Apr 25; 8(17):27754-27771. PubMed ID: 27487141
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
    Bao Z, Chen L, Guo S.
    J Cell Biochem; 2019 Jun 25; 120(6):10205-10214. PubMed ID: 30592329
    [Abstract] [Full Text] [Related]

  • 13. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
    Deng Y, Zhu H, Xiao L, Liu C, Meng X.
    Aging (Albany NY); 2020 Dec 09; 13(2):2198-2211. PubMed ID: 33316781
    [Abstract] [Full Text] [Related]

  • 14. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec 09; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y, Li H, Yi D, Sun Y, Bai Y, Zhong S, Song Y, Zhao G, Chen Y.
    Mol Pharm; 2018 Nov 05; 15(11):4912-4925. PubMed ID: 30336060
    [Abstract] [Full Text] [Related]

  • 16. BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.
    Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, Weichselbaum RR, Yamini B.
    Sci Transl Med; 2018 Jul 04; 10(448):. PubMed ID: 29973405
    [Abstract] [Full Text] [Related]

  • 17. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
    Chen Z, Zhou J, Liu Y, Ni H, Zhou B.
    Drug Dev Res; 2023 Nov 04; 84(7):1482-1495. PubMed ID: 37551766
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z, Chen Y, Wang S, Li P, Zhou G, Yuan Y.
    Cancer Lett; 2018 Aug 01; 428():77-89. PubMed ID: 29705182
    [Abstract] [Full Text] [Related]

  • 19. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
    Tomar VS, Patil V, Somasundaram K.
    Cell Biol Toxicol; 2020 Jun 01; 36(3):273-278. PubMed ID: 31758290
    [Abstract] [Full Text] [Related]

  • 20. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
    Chen L, Han L, Shi Z, Zhang K, Liu Y, Zheng Y, Jiang T, Pu P, Jiang C, Kang C.
    Mol Med Rep; 2012 Feb 01; 5(2):575-9. PubMed ID: 22086271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.